Immortal Dragons, a longevity fund based in Singapore, has declared its strategic investment in Unlimited Bio, a biotechnology firm focused on developing combinatorial therapies to combat the complexities of aging. This announcement was made on October 22, 2025.
Unlimited Bio employs a unique platform that combines various therapeutic approaches, including gene therapies, biologics, plasma-based treatments, cell therapies, and small-molecule drugs. The company targets complementary mechanisms across different organ systems to address the multi-faceted nature of aging. Their strategy is centered on the idea that aging is a result of multiple biological systems failing simultaneously, necessitating a broad and synergistic combination of interventions across various tissues and pathways.
The current gene therapy offerings include VEGF-A and Follistatin for vascular and muscular health, along with α-Klotho and BDNF for cognitive and neuroprotective functions. The VEGF-A gene therapy, which is an approved treatment repurposed to enhance vascular health, has shown significant improvements in pain-free walking distances among patients suffering from peripheral ischemia. Since its introduction in 2011, it has been administered to numerous patients, establishing a solid safety record through extensive post-marketing data.
Ivan Morgunov, CEO of Unlimited Bio, remarked, “Aging is not a single pathway but a multi-system failure involving interdependent biological networks.” He emphasized that their approach treats this issue as an engineering problem that requires an integrated and synergistic system to enable the safe combination of numerous interventions.
This investment aligns with Immortal Dragons” commitment to engineering-based strategies aimed at significantly extending human lifespan. While the fund”s existing portfolio focuses on organ failure through technologies like 3D biofabrication and artificial wombs, Unlimited Bio“s work targets the fundamental mechanisms of biological aging, potentially enhancing the functional lifespan of both natural and engineered tissues.
To facilitate further clinical validation, trials will be conducted in Special Economic Zones, particularly at Prospera ZEDE, where surrogate endpoints in healthy volunteers will allow for cost-effective studies that adhere to stringent safety standards.
Looking forward, Unlimited Bio aims to initiate its first clinical trial in late 2025 or early 2026, which will be the first of its kind combining two gene therapies in healthy individuals. This study intends to demonstrate the safety and combined rejuvenative potential of multi-gene interventions, thereby serving as a proof-of-concept for future research.
The company plans to expand its integrated therapeutic offerings across various biological levels, creating a platform that can continuously adapt to new discoveries in longevity science and optimize intervention synergies over the next decade.
Immortal Dragons is dedicated to supporting innovative technologies and promoting longevity through various initiatives, including publishing and hosting educational content related to longevity.
